Protara Therapeutics (NASDAQ:TARA) Coverage Initiated by Analysts at Lifesci Capital

Lifesci Capital started coverage on shares of Protara Therapeutics (NASDAQ:TARA) in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage issued an outperform rating and a $22.00 target price on the stock.

A number of other equities analysts have also weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a research note on Thursday, March 6th. Guggenheim restated a “buy” rating and set a $20.00 price objective on shares of Protara Therapeutics in a research note on Friday, December 6th.

Protara Therapeutics Trading Up 9.3 %

Shares of NASDAQ TARA opened at $4.10 on Tuesday. The firm has a market cap of $84.58 million, a PE ratio of -1.45 and a beta of 1.69. Protara Therapeutics has a 1-year low of $1.60 and a 1-year high of $10.48. The company has a fifty day moving average price of $4.51 and a 200 day moving average price of $3.45.

Protara Therapeutics (NASDAQ:TARA) last announced its earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.09. Equities research analysts forecast that Protara Therapeutics will post -3.32 EPS for the current year.

Hedge Funds Weigh In On Protara Therapeutics

A number of large investors have recently modified their holdings of TARA. XTX Topco Ltd bought a new stake in shares of Protara Therapeutics in the 3rd quarter valued at about $60,000. HBK Investments L P bought a new stake in shares of Protara Therapeutics in the 4th quarter valued at about $106,000. Squarepoint Ops LLC bought a new stake in shares of Protara Therapeutics in the 4th quarter valued at about $110,000. Dimensional Fund Advisors LP bought a new stake in shares of Protara Therapeutics in the 4th quarter valued at about $111,000. Finally, Bailard Inc. bought a new stake in shares of Protara Therapeutics in the 4th quarter valued at about $157,000. 38.13% of the stock is currently owned by institutional investors and hedge funds.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.